Clinical trials: Hematopoietic Stem Cell Mobilization
Healthy
Oxidative Stress as an Acute Exercise-induced Mechanism of Stem and Progenitor Cell Mobilization
It is already known from literature that exercise mobilizes stem and progenitor cells into the peripheral blood. However, the exact mechanisms thereof remain to be fully elucidated.
- Trial name
- EISMO (NCT03747913)
- Testing
- Antioxidative supplementation
- Where
- Switzerland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Lymphoma, Non-Hodgkin, Hodgkin Disease
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
This study will evaluate the safety and efficacy of intravenous AMD3100 added to a standard G-CSF mobilization regimen of patients undergoing autologous stem cell transplantation for lymphoma.
- Trial name
- NCT00733824
- Testing
- AMD3100, G-CSF, Apheresis
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
This study includes extended CD34+ profiling on the apheresis product of multiple myeloma patients undergoing standard-of-care quad-induction followed by motixafortide + G-CSF mobilization, and in addition, assesses the…
- Trial name
- NCT06547112
- Testing
- Motixafortide, G-CSF
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Non-Hodgkin's Lymphoma
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
The study is to determine if NHL patients mobilized with G-CSF (10 µg/kg/day [GRAN® only]) plus 0.24 mg/kg/day of plerixafor are more likely to achieve a target number of ≥5 × 10^6 CD34+ cells/kg in 4 or fewer days of apheresis…
- Trial name
- NCT01767714
- Testing
- Granulocyte-colony stimulating factor (G-CSF), Plerixafor
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Sanofi
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
The purpose of the study is to compare safety and efficacy of stem cell mobilization using G-CSF (filgrastim) alone vs. intermediate-dose cytosine arabinoside plus G-CSF in Hodgkin's lymphoma and non-Hodgkin's lymphoma patients.
- Trial name
- NCT02722733
- Testing
- G-CSF (filgrastim), Cytosine arabinoside with G-CSF (filgrastim)
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Graft vs Host Disease, Hematologic Neoplasms
HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies
Many patients with hematological malignancies potentially curable by bone marrow transplantation are not considered for transplantation because an HLA identical family or unrelated donor is unavailable.
- Conditions
- Graft vs Host Disease, Hematologic Neoplasms, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00001748
- Testing
- Peripheral blood progenitor cell transplant
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509
The primary and secondary objectives of this study are: Primary: To evaluate stem-cell-mobilization in subjects with diabetic neuropathy receiving SB-509.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00665145
- Testing
- SB-509
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Sangamo Therapeutics
Aging
A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging
This study aims to assess the impact of hyperbaric oxygen therapy on a number of outcomes, including epigenetic aging, inflammation, and cellular health.
- Trial name
- HBOT (NCT05297019)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- TruDiagnostic
Peripheral Vascular Diseases
Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease
This study is designed to test the use of G-CSF in peripheral vascular disease. The investigators hypothesize that mobilization of angiogenic cells into the blood by granulocyte colony stimulating factor (G-CSF) may stimulate the…
- Trial name
- STEMPAD (NCT00797056)
- Testing
- G-CSF, Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Washington University School of Medicine
Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia
Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients
The purpose of this study is to assess the tolerance and efficacy of mobilizing hematopoietic stem cells after a single injection of plerixafor (0.24mg/kg) in 3 adult patients (or 5, if results of the first 3 patients are not…
- Trial name
- DrepaMob (NCT02212535)
- Testing
- Plerixafor
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy
AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation
Peripheral blood progenitor cells (PBPC) have become the preferred source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and shorter time required for engraftment.
- Trial name
- NCT00075335
- Testing
- AMD3100 (Mozobil plerixafor)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be…
- Trial name
- NCT06442761
- Testing
- Motixafortide
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- St. Jude Children's Research Hospital
Plasma Cell Myeloma
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization.
- Trial name
- NCT04211259
- Testing
- Loratadine, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Rutgers, The State University of New Jersey
Sickle Cell Disease
STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE
The objective of this study is to demonstrate whether high-dose plerixafor can effectively mobilize hematopoietic stem cells in patients with sickle cell disease.
- Trial name
- MobiSCD (NCT07341022)
- Testing
- Plerixafor Dose Escalation
- Volunteers
- 12 people
- Sponsor
- Hospital Israelita Albert Einstein
Myocardial Infarction
Study on the Efficacy and Mechanism of Cardiac Rehabilitation for Stem Cell Mobilization and Heart Failure Improvement
One emerging concept is that some form of injury or inflammation is a prerequisite for the success of circulating-cell participation in differentiated tissue structure and function.
- Trial name
- NCT00154466
- Testing
- cardiac rehabilitation
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- National Taiwan University Hospital
Sickle Cell Disease, Thalassemia
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Background: Some sickle cell disease or beta-thalassemia can be cured with transplant. Researchers want to test a variation of transplant that uses low dose radiation and a combination of immunosuppressive drugs.
- Conditions
- Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
- Trial name
- NCT02105766
- Testing
- Alemtuzumab, Sirolimus, Cyclophosphamide
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL
RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00274794
- Testing
- filgrastim, rituximab
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- The Cleveland Clinic
Leukemia
Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>
RATIONALE: Transplanted peripheral stem cells can sometimes be rejected by the body's tissues. Treating donor peripheral stem cells with filgrastim may increase the number of donor white blood cells.
- Trial name
- NCT00025545
- Testing
- cyclophosphamide, methotrexate, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center